Silence Therapeutics (SLN) Assets Average (2019 - 2026)

Silence Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $123.3 million for Q1 2026.

• In Q1 2026, Assets Average fell 36.44% year-over-year to $123.3 million; the TTM figure through Mar 2026 stood at $123.3 million (down 36.44% YoY), while the FY2025 annual figure was $167.0 million, up 3.72% from the prior year.
• Assets Average came in at $123.3 million for Q1 2026 at Silence Therapeutics, down from $139.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $773.2 million in Q3 2024 to a low of $123.3 million in Q1 2026.
• A 5-year average of $402.9 million and a median of $476.0 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 88.86% in 2022 and slumped 79.82% in 2025, its largest moves.
• Silence Therapeutics' Assets Average stood at $495.5 million in 2022, then retreated by 3.94% to $476.0 million in 2023, then advanced by 7.54% to $511.9 million in 2024, then sank by 72.82% to $139.1 million in 2025, then retreated by 11.38% to $123.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $123.3 million, $139.1 million, and $156.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison